ANTENGENE-B - VOLUNTARY ANNOUNCEMENT

IND APPROVAL FOR ATG-201 (CD19 x CD3 TCE) IN AUTOIMMUNE DISEASE IN CHINA

Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

IND APPROVAL FOR ATG-201 (CD19 × CD3 TCE) IN

AUTOIMMUNE DISEASE IN CHINA

This announcement is made by Antengene Corporation Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board of directors of the Company (the "Board") is pleased to announce that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the Phase I study of ATG-201, a CD19/CD3 bispecific T-cell engager antibody, for the treatment of B cell related autoimmune diseases. Antengene plans to promptly initiate and advance the Phase I study in China, while concurrently preparing for the clinical development of ATG-201 in Australia.

The Group cannot guarantee that ATG-201 will ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By the order of the Board

Antengene Corporation Limited Dr. Jay Mei

Chairman

Hong Kong, June 10, 2026